Blockad av TNF alpha--ny behandlingsprincip vid svår reumatoid artrit

P. Larsson; J. Bratt; A. Harju; R. van Vollenhoven; L. Klareskog

Blockad av TNF alpha--ny behandlingsprincip vid svår reumatoid artrit

P. Larsson, J. Bratt, A. Harju, R. van Vollenhoven, L. Klareskog

Research output: Contribution to journal › Article › Academic › peer-review

1 Citation (Scopus)

Abstract

TNF-alpha is a proinflammatory cytokine. It has a key function in the inflammatory cascade both systemically and locally in the inflamed joints of patients affected by rheumatoid arthritis (RA). Treatment with two different "biological" drugs that block the proinflammatory capacity of TNF-alpha has recently been approved by the European drug authorities. This paper discusses experience gained in clinical trials and during the first year of treatment in Sweden using infliximab (anti-TNF-alpha monoclonal antibodies) and etanercept (recombinant TNF-alpha receptor fusion protein)

Original language	English
Pages (from-to)	828-831
Journal	Lakartidningen
Volume	98
Issue number	8
Publication status	Published - 2001
Externally published	Yes

Cite this

@article{8b9db0636b1a40178e24e0e75fccab40,

title = "Blockad av TNF alpha--ny behandlingsprincip vid sv{\aa}r reumatoid artrit",

abstract = "TNF-alpha is a proinflammatory cytokine. It has a key function in the inflammatory cascade both systemically and locally in the inflamed joints of patients affected by rheumatoid arthritis (RA). Treatment with two different {"}biological{"} drugs that block the proinflammatory capacity of TNF-alpha has recently been approved by the European drug authorities. This paper discusses experience gained in clinical trials and during the first year of treatment in Sweden using infliximab (anti-TNF-alpha monoclonal antibodies) and etanercept (recombinant TNF-alpha receptor fusion protein)",

author = "P. Larsson and J. Bratt and A. Harju and {van Vollenhoven}, R. and L. Klareskog",

year = "2001",

language = "English",

volume = "98",

pages = "828--831",

journal = "Lakartidningen",

issn = "0023-7205",

publisher = "Swedish Medical Association",

number = "8",

}

TY - JOUR

T1 - Blockad av TNF alpha--ny behandlingsprincip vid svår reumatoid artrit

AU - Larsson, P.

AU - Bratt, J.

AU - Harju, A.

AU - van Vollenhoven, R.

AU - Klareskog, L.

PY - 2001

Y1 - 2001

N2 - TNF-alpha is a proinflammatory cytokine. It has a key function in the inflammatory cascade both systemically and locally in the inflamed joints of patients affected by rheumatoid arthritis (RA). Treatment with two different "biological" drugs that block the proinflammatory capacity of TNF-alpha has recently been approved by the European drug authorities. This paper discusses experience gained in clinical trials and during the first year of treatment in Sweden using infliximab (anti-TNF-alpha monoclonal antibodies) and etanercept (recombinant TNF-alpha receptor fusion protein)

AB - TNF-alpha is a proinflammatory cytokine. It has a key function in the inflammatory cascade both systemically and locally in the inflamed joints of patients affected by rheumatoid arthritis (RA). Treatment with two different "biological" drugs that block the proinflammatory capacity of TNF-alpha has recently been approved by the European drug authorities. This paper discusses experience gained in clinical trials and during the first year of treatment in Sweden using infliximab (anti-TNF-alpha monoclonal antibodies) and etanercept (recombinant TNF-alpha receptor fusion protein)

M3 - Article

C2 - 11265568

SN - 0023-7205

VL - 98

SP - 828

EP - 831

JO - Lakartidningen

JF - Lakartidningen

IS - 8

ER -